Kouros Owzar, Ph.D.

Department:
Biostatistics and Bioinformatics

Email Address:
kouros.owzar@duke.edu

Address:
DUMC Box 2721

Durham, NC 27710

Telephone:
9196811829

Research Interests:
statistical genetics
statistical methods for high-dimensional data
pharmacogenomics
copulas
survival analysis
statistical computing

Publications:
2009 -- Pubmed # 19303137 -- Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, . Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104.

2009 -- Pubmed # 19380448 -- Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009 Jun 10;27(17):2766-71.

2009 -- Pubmed # 19414990 -- Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS. 2009 May 15;23(8):897-906.

2009 -- Pubmed # 19289999 -- Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, Larson RA. Auto-SCT for AML in second remission: CALGB Study 9620. Bone Marrow Transplant. 2009 Mar 16.

2009 -- Pubmed # 19255312 -- Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ. Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301. J Clin Oncol. 2009 Mar 16.

2008 -- Pubmed # 19064574 -- Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87.

2008 -- Pubmed # 18082148 -- Gauter-Fleckenstein B, Fleckenstein K, Owzar K, Jiang C, Batinic-Haberle I, Vujaskovic Z. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med. 2008 Mar 15;44(6):982-9.

2008 -- Pubmed # 18955451 -- Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA. Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Oct 27.

2008 -- Pubmed # 18829474 -- Owzar K, Barry WT, Jung SH, Sohn I, George SL. Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res. 2008 Oct 1;14(19):5959-66.

2008 -- Pubmed # 18559411 -- Owzar K, Jung SH. Authors' response. Clin Trials. 2008;5(3):223-4.

2008 -- Pubmed # 18559409 -- Owzar K, Jung SH. Designing phase II studies in cancer with time-to-event endpoints. Clin Trials. 2008;5(3):209-21.

2008 -- Pubmed # 18349389 -- Owzar K. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. J Clin Oncol. 2008 Mar 20;26(9):1400-1.

2007 -- Pubmed # 17634483 -- Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol. 2007 Jul 20;25(21):3055-60.

2007 -- Pubmed # 17484778 -- Owzar K, Jung SH, Sen PK. A copula approach for detecting prognostic genes associated with survival outcome in microarray studies. Biometrics. 2007 Dec;63(4):1089-98.

2006 -- Pubmed # 17146978 -- Jung SH, Owzar K, George SL, Lee T. P-value calculation for multistage phase II cancer clinical trials. J Biopharm Stat. 2006;16(6):765-75; discussion 777-83.

2006 -- Pubmed # 16339184 -- Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS, Diehl AM. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis. 2006 Apr;27(4):748-57.

2005 -- Pubmed # 16189805 -- Jung SH, Owzar K, George SL. A multiple testing procedure to associate gene expression levels with survival. Stat Med. 2005 Oct 30;24(20):3077-88.

2005 -- Jung SH, Owzar K, George SL. Associating Microarray Data with a Survival Endpoint in
Methods of Microarray Data Analysis IV, Springer Verlag 2005.

2005 -- Pubmed # 16162881 -- Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med. 2005 Sep 15;353(11):1105-13.

2003 -- Owzar, K, Sen PK. Copulas: Concepts an novel applications. Metron 2003; 61: 1475-1489